Adaptogenics Health Corp. Announces Closing of Over Subscribed Non-Brokered Private Placement

Adaptogenics raised $327,000 in an oversubscribed private placement at $0.08 per share.

What the company is saying

Adaptogenics Health Corp. is announcing the successful closing of a non-brokered private placement, issuing 4,087,500 common shares at $0.08 per share for total gross proceeds of $327,000. The company highlights that the placement was oversubscribed, exceeding the original $320,000 target. Management states that the net proceeds will be used for general working capital, but does not provide a breakdown of specific uses. Two directors, unnamed in this release, participated directly by acquiring a combined 750,000 shares for $60,000, which is disclosed as a related party transaction under MI 61-101. The company emphasizes compliance with regulatory exemptions, stating that the directors' participation was below the 25% market capitalization threshold. All new shares are subject to a statutory hold period expiring January 29, 2027. The tone is factual and regulatory, with no forward-looking operational claims beyond intended use of funds.

What the data suggests

The company issued 4,087,500 new shares at $0.08 each, raising $327,000 in gross proceeds, surpassing the original $320,000 target. No finder's fees were paid, so the full amount is available for working capital. Director participation accounted for 750,000 shares and $60,000, or about 18% of the placement, and was structured within regulatory limits to avoid triggering formal valuation or minority approval requirements. The placement is modest in scale, suggesting limited dilution and a targeted capital injection rather than a transformative raise. All shares are subject to a four-month plus one day hold, restricting immediate liquidity for investors until January 29, 2027. The announcement provides no information on the company’s cash position, operational progress, or financial trajectory outside this financing event. The evidence supports a straightforward capital raise with clear regulatory compliance and no embellishment.

Analysis

The announcement is a factual disclosure of the closing of a non-brokered private placement, with all key figures (shares issued, price, gross proceeds, director participation) clearly stated and supported by the data. The only forward-looking statement is the intended use of proceeds for general working capital, which is standard and not promotional. There are no exaggerated claims about future growth, operational milestones, or outsized benefits. The tone is positive but proportionate to the event, and there is no evidence of narrative inflation or overstatement. No large capital outlay is paired with long-dated or uncertain returns; the funds raised are modest and for immediate working capital. The gap between narrative and evidence is negligible, as all material claims are realised and supported.

Risk flags

• ●The company provides no detail on how the $327,000 in proceeds will be allocated within working capital, leaving uncertainty about the impact on operations or growth.
• ●Director participation in the financing, while within regulatory limits, introduces potential governance and related party risks if future transactions are not as clearly disclosed or if oversight is insufficient.
• ●The modest size of the raise suggests that further financings may be needed to support significant operational initiatives, which could lead to future dilution or capital constraints.

Bottom line

Adaptogenics Health Corp. has completed a small, oversubscribed private placement, raising $327,000 at $0.08 per share, with two directors contributing $60,000. The process was handled with clear regulatory compliance, including related party transaction disclosure and adherence to MI 61-101 exemptions. There is no evidence of hype or overstatement, and the company does not provide operational or financial guidance beyond the intended use of proceeds for working capital. Investors should recognize that while the raise is positive for near-term liquidity, its scale is limited and the impact on future growth or profitability is not addressed. The most important takeaway is that the company has modestly strengthened its balance sheet, but the lack of detail on capital deployment and operational milestones means the announcement is not a catalyst for re-rating the stock. Future updates should provide more transparency on how new funds translate into business progress.

Announcement summary

(CSE:ADPT) Adaptogenics Health Corp. has closed its oversubscribed non-brokered private placement of 4,087,500 common shares at a price of $0.08 per share for aggregate gross proceeds of $327,000. The company had originally announced the private placement for gross proceeds of up to $320,000. The net proceeds from the private placement will be used for general working capital purposes. No finder's fees were paid in connection with the private placement. Two directors of the company acquired, directly, an aggregate of 750,000 shares under the private placement for aggregate gross proceeds of $60,000. The participation by the directors in the private placement constitutes a 'related party transaction' within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (MI 61-101). The company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a), as neither the fair market value of the shares issued to the directors, nor the consideration paid by the directors, exceeds 25% of the company's market capitalization. All securities issued pursuant to the private placement are subject to a hold period of four months plus one day as required under applicable securities legislation, which expires on January 29, 2027. Hani Zabaneh is the COO and Director of Adaptogenics Health Corp.

Disagree with this article?